Ocular Therapeutix Confirms AXPAXLI NDA Timeline After Positive FDA Meeting

Key Facts

1Ocular Therapeutix confirmed its plan to submit a New Drug Application (NDA) for AXPAXLI in Q4 2026.

2The drug targets wet age-related macular degeneration (wet AMD) with a potential commercial launch in 2027.

In a move that strengthens regulatory confidence within the biotech sector, Ocular Therapeutix announced the successful completion of a Pre-NDA meeting with the U.S. Food and Drug Administration (FDA). According to reports, the company confirmed its plan to submit a New Drug Application (NDA) for AXPAXLI, a treatment for wet age-related macular degeneration (wet AMD), in the fourth quarter of 2026. This meeting aligns clinical data from the SOL-1 and SOL-R trials with formal FDA submission requirements.

This progress reflects a reduction in clinical uncertainty for the company's lead candidate, with a potential commercial launch targeted for 2027 pending approval. These developments occur as the healthcare sector seeks more sustainable treatments for chronic ophthalmic conditions, positioning AXPAXLI competitively within this specialized market.

OCUL shares stood at $10.72 at the close of September 14, 2026, with the stock trading between a day low of $10.49 and a high of $10.85 per market data. Investors will be watching for the completion of technical filing requirements as the next major catalyst, while broader markets digest recent macroeconomic data including the U.S. Producer Price Index (PPI), which recently printed at 0.4%.